![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Heavy Drinking Can Damage Every Part of the Eye
Jun 24, 2022 · Tori Rodriguez, MA, LPC, AHC, is an Atlanta-based journalist, licensed psychotherapist, and Ayurvedic health coach, creator of the body-positive wellness company Bettie Page Fitness, and author of 2 books – The Little Book of Bettie: Taking a Page from the Queen of Pinups and Bettie Page: The Lost Years.
Photobiomodulation Treatment for Dry AMD Approved By FDA ...
Nov 15, 2024 · A photobiomodulation therapy device has received approval by the US Food and Drug Administration (FDA) to be marketed for the treatment of nonexudative (dry) age-related macular degeneration (AMD), according to statements from the FDA and the manufacturer.The device allows physicians the opportunity to offer a noninvasive treatment for dry AMD with a low-level laser therapy (LLLT) technology. 1,2
Methotrexate May Lower Risk of Retinal Detachment Repair …
Dec 17, 2024 · Systemic methotrexate and azathioprine therapies are associated with a lower risk of proliferative vitreoretinopathy (PVR) development within 6 months of primary retinal detachment, according to the results of a multicenter retrospective cohort study published in Ophthalmology Retina.. PVR is a predominant cause of failure for repair of retinal detachment.
Ocular Myasthenia Gravis Treatment Options Explained
Jul 20, 2023 · Myasthenia gravis (MG) can occur in 2 forms: a generalized myasthenia gravis (GMG) or purely ocular myasthenia gravis (OMG). Ocular myasthenia gravis is characterized by progressive fatigability of skeletal muscle limited to the orbicularis oculi, levator palpebrae superioris, and the extraocular muscles. 1 Up to half of patients diagnosed with MG present with ocular muscle weakness before ...
Generic Latanoprost Receives FDA Approval for Glaucoma, OHT ...
Dec 4, 2024 · The Food and Drug Administration (FDA) has approved a generic latanoprost, a prostaglandin analogue, for the treatment of open-angle glaucoma and ocular hypertension, according to a pharmaceutical manufacturer’s press release.The announcement from Gland Pharma Limited says that the FDA has found the generic latanoprost both bioequivalent and therapeutically equivalent to Xalatan ...
Intraocular Lens Choice Dependent on Lifestyle, Expectations ...
Oct 4, 2024 · Cataract surgeons are responsible for advising patients on a decision that will have lifelong implications. Identifying the intraocular lens (IOL) choice most suited for a particular patient’s lifestyle should be done with the patient’s careful consideration, and full understanding of the portfolio of options before them.
ADHD and Vision Disorders Have Pathogenic, Behavioral Links
Nov 10, 2024 · The study analyzed medical records of 940,763 individuals and found that ADHD was more prevalent among people with keratoconus compared with among the whole cohort (0.24% vs 0.16%). 7 The study also shows that people with keratoconus are approximately 1.6 times more likely to be diagnosed with ADHD.
Preservative-Free Sodium Hyaluronate Drop Improves Dry Eye for …
Nov 20, 2023 · Preservative-free sodium hyaluronate (0.4%) eye drops in different dosages effectively alleviates signs and symptoms of dye eye disease (DED) after 1 month of treatment in approximately 50% of patients, according to a study published in Clinical Ophthalmology.. Researchers investigated the effectiveness of the preservative-free sodium hyaluronate drops in a randomized, parallel assignment ...
Photobiomodulation: An Emerging Dry AMD Treatment
Mar 20, 2024 · A Future in AMD Management. There are some limitations in comparing these results to other photobiomodulation studies, including varying wavelengths, time intervals of treatment , and length of sessions across different studies, as well as lack of specificity regarding which stage of AMD the treatment is best targeted towards.
Empagliflozin Has Lower Diabetic Retinopathy Risk Than DPP4is ...
Dec 6, 2024 · Patients with type 2 diabetes mellitus (T2D) who are treated with empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), are less likely to progress from nonproliferative to proliferative diabetic retinopathy than those treated with a dipeptidyl peptidase 4 inhibitor (DPP4i), according to research published in JAMA Ophthalmology.The study also found that new nonproliferative ...